Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:24 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2593–2616 of 8,279 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Age Clear all

Conditions: Brain Injuries, Traumatic
Interventions: Head and Intraocular Trauma Tool; Device
Lead sponsor: Rebiscan, Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Cutaneous Melanoma
Interventions: Demographics Questionnaire, Adjuvant Treatment Beliefs Scale10, Functional Assessment of Cancer Therapy - Melanoma (FACT-M)11, Functional Assessment of Chronic Illness Therapy - Treatment Satisfaction - General (FACIT-TS-G)13, Decisional Regret14, Clinician Preference for Treatment; Behavioral
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 3
States / cities: Basking Ridge, New Jersey • Harrison, New York • New York, New York

Conditions: Atherosclerotic Disease, Carotid
Interventions: Not listed
Lead sponsor: VPDiagnostics; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 15
States / cities: Phoenix, Arizona • Los Angeles, California • San Francisco, California + 10 more

Conditions: Constipation
Interventions: Prucalopride, Placebo; Drug · Other
Lead sponsor: Takeda; Industry
Eligibility: 6 Months to 17 Years
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 41
States / cities: Phoenix, Arizona • Tucson, Arizona • Anaheim, California + 32 more

Conditions: E-Cig Use
Interventions: Hyperpolarized Xenon -129 MRI; Drug
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Aging
Interventions: Sirolimus, Metformin, Diclofenac; Drug
Lead sponsor: Anne Chang; Other
Eligibility: 55 Years and older · Female only
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Redwood City, California

Conditions: Cannabis Use, Cannabis Intoxication, Cannabis Use Disorder
Interventions: Biologic testing for THC; Other
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 18 Years to 35 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Dermatitis Atopic
Interventions: Amlitelimab, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 12 Years and older
Enrollment: 589 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 43
States / cities: Scottsdale, Arizona • Tucson, Arizona • Lomita, California + 38 more

Conditions: Age-related Wet Macular Degeneration
Interventions: CG-P5 peptide, Placebo, Aflibercept Injection [Eylea]; Drug
Lead sponsor: Caregen Co. Ltd.; Industry
Eligibility: 50 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 7
States / cities: Manchester, Connecticut • Deerfield Beach, Florida • Augusta, Georgia + 4 more

Conditions: Hypotension and Shock, Pulmonary Hypertension of the Newborn (PPHN), Hypoxemic Respiratory Failure
Interventions: Dopamine administration, Norepinephrine; Drug
Lead sponsor: University of California, Davis; Other
Eligibility: Up to 28 Days
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Ageing
Interventions: Not listed
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 122 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Redwood City, California

Conditions: Medium-chain Acyl-CoA Dehydrogenase Deficiency
Interventions: Sodium phenylbutyrate; Drug
Lead sponsor: Jerry Vockley, MD, PhD; Other
Eligibility: 4 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: NAFLD, PCOS
Interventions: Bicalutamide 50 mg, Placebo; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 42 Years · Female only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Macular Degeneration
Interventions: Not listed
Lead sponsor: Vanderbilt University; Other
Eligibility: 55 Years to 85 Years
Enrollment: 143 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Retinopathy of Prematurity (ROP)
Interventions: myo-Inositol 5% Injection, Placebo; Drug
Lead sponsor: NICHD Neonatal Research Network; Network
Eligibility: 12 Hours to 72 Hours
Enrollment: 638 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 19
States / cities: Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 15 more

Conditions: Prematurity, Anemia, Necrotizing Enterocolitis
Interventions: Not listed
Lead sponsor: Duke University; Other
Eligibility: Up to 365 Days
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Human Papillomavirus
Interventions: Not listed
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 9 Years to 26 Years · Female only
Enrollment: 587 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Spinal Muscular Atrophy, Spinal Muscular Atrophy Type 3, Spinal Muscular Atrophy Type 2, SMA, Neuromuscular Diseases, Muscular Atrophy, Atrophy, Muscular Atrophy, Spinal, Neuromuscular Manifestations, Anti-myostatin
Interventions: Apitegromab, Placebo; Drug
Lead sponsor: Scholar Rock, Inc.; Industry
Eligibility: 2 Years to 21 Years
Enrollment: 188 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 26
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 23 more

Conditions: Asthma
Interventions: Fluticasone Furoate, Fluticasone Furoate/Vilanterol; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 5 Years to 11 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Huntington Beach, California

Conditions: Substance Use
Interventions: Better Together, Youth In the Media (YM); Behavioral
Lead sponsor: Johns Hopkins Bloomberg School of Public Health; Other
Eligibility: 11 Years to 13 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Autism, Gastro Intestinal Diseases
Interventions: Not listed
Lead sponsor: The Center for Discovery; Other
Eligibility: 5 Years to 19 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Harris, New York

Conditions: Congenital Diaphragmatic Hernia
Interventions: Goldballoon Detachable Balloon and delivery microcatheter; Device
Lead sponsor: Michael A Belfort; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2023
U.S. locations: 1
States / cities: Houston, Texas

Conditions: HIV-ASSOCIATED NEUROCOGNITIVE DISORDER (HAND)
Interventions: Not listed
Lead sponsor: East Tennessee State University; Other
Eligibility: 25 Years to 75 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Johnson City, Tennessee

Conditions: Moderate-to-Severe Atopic Dermatitis
Interventions: Nemolizumab; Drug
Lead sponsor: Galderma R&D; Industry
Eligibility: 6 Months to 23 Months
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: San Antonio, Texas

Search by objective public record fields.

mTBI Identification and Monitoring Through Retinal Scanning

A Study To See Why Patients Agree To or Decline To Have Treatment After Surgery

SmartRisk Stroke Prediction by MRI of Carotid Disease

A Study of Prucalopride For Functional Constipation in Children and Teenagers

Hyperpolarized Xenon-129 MR Imaging of the Lung

Phase 1 Study of the Effects of Combining Topical FDA-approved Drugs on Age-related Pathways on the Skin of Healthy Volunteers

Study of an Oral Fluid Testing Approach

A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis (COAST 2)

Study to Evaluate the Safety of CG-P5 Peptide Eye Drops in Patients Diagnosed With Age-related Wet Macular Degeneration

Dopamine vs. Norepinephrine for Hypotension in Neonates With Pulmonary Hypertension (DONE)

Human Skin Aging: Clinical Parameters and Gene Expression Profiling

Study of Sodium Phenylbutyrate (ACER-001) for the Treatment of Pediatric and Adults Patients With Medium Chain Acyl-CoA Dehydrogenase Deficiency (MCADD)

Bicalutamide Therapy in Young Women With NAFLD and PCOS

Antioxidant Systems and Age-Related Macular Degeneration

Inositol to Reduce Retinopathy of Prematurity

Transfusions and Nitric Oxide Level in Preterm Infants

Human Papillomavirus (HPV) Vaccination Among Survivors of Childhood Cancer

Efficacy and Safety of Apitegromab in Patients With Later-Onset Spinal Muscular Atrophy Treated With Nusinersen or Risdiplam

Inhaled Fluticasone Furoate/Vilanterol Safety and Tolerability, PK and PD Study

Test of the Better Together Intervention

Identifying Biomarkers of Gastro Intestinal Comorbidities in Autism Spectrum Disorder

Fetal Endotracheal Occlusion (FETO) in Severe and Extremely Severe Congenital Diaphragmatic Hernia

Prevalence of HIV-associated Neurocognitive Disorders (HAND) in a School of Medicine HIV/AIDS Outpatient Clinic

Pharmacokinetics, Safety and Efficacy of Nemolizumab in Participants Aged 6 to 23 Months With Moderate-to Severe Atopic Dermatitis